Patent SG-11201909498X-A (SG)
Title: T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
Inventor: LISSILAA RAMI
IPC: C07K16/46
Filed: 2018-04-24
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 November 2018 (01.11.2018) WIPO I PCT ill 1111u°11101VIIIVIIIVIIIolo VIII oimIE (10) International Publication Number WO 2018/197502 Al (51) International Patent Classification: C07K 16/28 (2006.01) C07K 16/46 (2006.01) (21) International Application Number: PCT/EP2018/060488 (22) International Filing Date: 24 April 2018 (24.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17167709.9 24 April 2017 (24.04.2017) EP (71) Applicant: GLENMARK PHARMACEUTICALS S.A. [CH/CH]; Chemin de la Combeta 5, 2300 La Chaux-de- Fonds (CH). (72) Inventors: LISSILAA, Rami; Chemin de la Combeta 5, 2300 La Chaux-de-Fonds (CH). STUTZ, Cian; Chemin de la Combeta 5, 2300 La Chaux-de-Fonds (CH). (74) Agent: THOMAS, Dean; Glenmark Pharmaceuticals S.A., Chemin de la Combeta 5, 2300 La Chaux-de-Fonds (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: T CELL REDIRECTING BISPECIFIC ANTIBODIES FOR THE TREATMENT OF EGFR POSITIVE CANCERS Figure 1 EGFR A. B AB AR A6 CD3xF.Gia 1 C 3Y.E*F.R.S51 CDIKEGF R_SF3 0:0;‘,/{5Fic Sid; EGF r EGCI 00 O O 13 A S R CO3xFC,FR_SDI CD; CD4y.1 , 61-R, (57) : The present invention relates to bispecific antibodies which bind to CD3 and EGFR simultaneously. This class of an- tibody has been demonstrated by the inventors to be useful in the treatment of EGFR tumors by redirecting T cells and forming an immune synapse between activated T cells and EGFR expressing tumor cells, leading to increased levels of killing of EGFR express- ing tumor cells. In particular the present invention relates to CD3xEGFR bispecific antibodies selected from the group comprising CD3xEGFR_SF1 (SEQ ID NO: 4, 5 and 6), CD3xEGFR_SF3 (SEQ ID NO: 7, 2 and 8), CD3xEGFR_SF4 (SEQ ID NO: 4, 5 and 9), CD3xEGFR_SD1 (SEQ ID 10 NO: 1, 2 and 10) and CD3xEGFR_SID2 (SEQ ID NO: 11, 10 and 2). [Continued on next page] WO 2018/197502 Al MIDEDIMOMMIDIIMMOIDEMIMOMMIRIHINVOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))